Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-68,800
Closed -$9.24M 1620
2021
Q4
$9.24M Buy
+68,800
New +$9.89M 0.05% 291
2021
Q1
Sell
-27,600
Closed -$2.55M 1711
2020
Q4
$2.55M Buy
+27,600
New +$2.46M 0.02% 628
2020
Q1
Sell
-68,000
Closed -$3.72M 2181
2019
Q4
$3.72M Hold
68,000
0.03% 672
2019
Q3
$2.54M Buy
+68,000
New +$2.64M 0.02% 928
2018
Q4
Sell
-87,600
Closed -$3.13M 2236
2018
Q3
$3.13M Buy
+87,600
New +$2.72M 0.02% 765
2015
Q3
Sell
-288,800
Closed -$5.78M 2456
2015
Q2
$5.78M Buy
+288,800
New +$5.07M 0.03% 463

Other funds holding DXCM

Jefferies Group's DXCM Position: Q3 2022 in Review

Jefferies Group opened a new position in DexCom (DXCM) in Q3 2022: 9,516 shares worth $766K. The stake represents 0.01% of the portfolio and ranks #882 among its holdings. This is a return to the name: Jefferies Group previously reported a position in DXCM as recently as Q1 2022.

Jefferies Group first reported a position in DXCM in Q4 2013 and has held it in 21 quarters since. The position peaked at $28.5M in Q3 2021. 794 funds tracked by Wall St. Rank hold DXCM as of Q3 2022.

  • Jefferies Group held 9,516 shares of DexCom worth $766K as of Q3 2022.
  • DexCom was a new Jefferies Group position in Q3 2022.
  • DexCom made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #882 holding.
  • Jefferies Group first reported a position in DexCom in Q4 2013 and has held it in 21 quarters since.
  • Jefferies Group's DexCom position peaked at $28.5M in Q3 2021.
  • 794 funds tracked by Wall St. Rank held DexCom as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.